Navigation Links
First FLEXUS(TM) Interspinous Spacer Surgeries for IDE Clinical Trial

AUDUBON, Pa., Aug. 15 /PRNewswire/ -- Globus Medical, Inc., the largest privately held spinal implant manufacturer in the world, today announced that the first FLEXUS(TM) Interspinous Spacers have been implanted under an Investigational Device Exemption ("IDE") recently granted to Globus by Dr. Donald Johnson II and Dr. Rhett Murray.

The FLEXUS(TM) Spacer is placed with a unilateral approach between two spinous processes with minimal disruption to the surrounding musculature and tissue. FLEXUS(TM) is a unitary radiolucent implant that requires no intra-operative assembly and a single incision to insert. It is manufactured from PEEK radiolucent polymer rather than titanium to more closely match the biomechanical properties of bone and eliminate MRI scatter.

"FLEXUS(TM) is the culmination of utilizing surgeon input and engineering simplicity to create innovative technologies to treat spinal stenosis. The FLEXUS(TM) IDE reflects Globus' position as the worldwide leader in the development of posterior motion preservation devices. We are excited to begin the clinical trial to develop strong supportive data for the product," said Michael Boyer, Group Engineering Manager for Interlaminar Fixation.

"The combination of a unilateral approach and a unitary implant makes FLEXUS(TM) not only a more efficient procedure but also one that is less traumatic to the patient," said Dr. Donald Johnson II, a spine surgeon of the Southeastern Spine Institute in Mt. Pleasant, S.C. "I am pleased with the PEEK design as it will enable better radiographic follow-up and allow me to monitor both the decompression and the adjacent anatomy."

After implanting the first FLEXUS(TM) device, Dr. Rhett Murray, a neurosurgeon of The Spine and Neurosurgery Center in Huntsville, Ala., said, "The surgical technique and approach was very straightforward. The simplicity of the FLEXUS(TM) design in distracting the stenotic segment may be beneficial in treating this painful condition. We are excited to participate in this IDE."

The 340 patient prospective, randomized FLEXUS(TM) IDE study will seek to prove equivalence with the X-Stop device over the two year study period. The study will involve patients that are over 50 years old who may benefit from the decompression provided by the FLEXUS(TM) device, at up to 20 clinical sites across the United States.

About Globus Medical, Inc.

Globus Medical, Inc. is the largest privately held spinal implant manufacturer in the world. Based in Audubon, Pa., the privately held company was founded in 2003 by an experienced team of spine professionals with a shared vision to create products that enable spine surgeons to employ both fusion and non-fusion solutions to promote healing in patients with spinal disorders. Globus Medical has a full portfolio of spinal fusion products, burgeoning initiatives in biomaterials development and minimally invasive approaches, and is among the world leaders in the development of motion sparing technology. Additional information can be accessed at

SOURCE Globus Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma
2. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
3. Alexion Secures U.S. Patent for ALXN6000, a First-In-Class Anti-CD200 Monoclonal Antibody
4. First DuraHeart(TM) Left Ventricular Assist System Implanted in the U.S. Pivotal Trial
5. First U.S. Patient to Receive New Heart-Assist Device Doing Well After Surgery at University of Michigan
6. MicroDose Technologies Announces Achievement of Phase I Clinical Milestone Triggering First Milestone Payment Under Collaboration with Merck & Co., Inc.
7. First Molecular Tem-PCR Test to Identify Multiple Forms of Staph and MRSA Obtains CLIA Certificate
8. Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US
9. First Ever Study on Alzheimers Disease Treatment in Hispanics Presented at Major Medical Meeting
10. Seattles Swedish Cancer Institute First in U.S. to Treat Cancer Patient with Elekta VMAT
11. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
Post Your Comments:
(Date:12/1/2015)... , Dec. 1, 2015 ... today announced that its Chief Executive Officer, ... the Oppenheimer Annual Healthcare Conference in New ... in the conference through a webcast on ... , --> ...
(Date:12/1/2015)... Pharma Tech Outlook recently conducted a comprehensive ... Management Solution Providers - 2015 .  After careful consideration ... CIOs, VCs, analysts, and the Pharma Tech Outlook editorial ... 10 clinical data management solution providers (check out the ... 36 respectively). --> ...
(Date:12/1/2015)... , 1 de diciembre de 2015 /PRNewswire/ ... para cuchillas de precisión, develó hoy un ... identidad de marca. El nuevo logo destaca ... y la ingeniería de productos con cuchillas ... ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... World Patent Marketing , ... a container patent that allows for easier packing and organizing of items into one ... $90 billion," says Scott Cooper, CEO and Creative Director of World Patent Marketing and ...
(Date:12/1/2015)... ... December 01, 2015 , ... Integrated Rental Services ... Jordan Industries International, LLC (“JII”). , With support from JII, Integrated Rental is ... to hospitals, surgery centers, clinics, research labs and medical facilities across the United ...
(Date:12/1/2015)... Fla. (PRWEB) , ... December 01, 2015 , ... ... number of leadless pacemakers in the U.S. and is the only hospital in ... from the largest clinical data presentation of transcatheter pacing patients were revealed recently ...
(Date:12/1/2015)... ... December 01, 2015 , ... Growth in medical payments per workers’ compensation ... utilization of hospital and nonhospital care, according to a recent study by the Workers ... 16th Edition , found medical payments per claim with more than seven days of ...
(Date:12/1/2015)... ... ... It’s official: Tattoo taboo is a thing of the past. One in five ... one in three aged 18 to 25 is inked). As tattoos transition to mainstream ... fact, RealSelf , the world’s largest community for learning and sharing information about ...
Breaking Medicine News(10 mins):